Loading clinical trials...
Loading clinical trials...
An Investigator-Initiated Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of CGRP Antagonists in Patients With Dry Eye Disease and Asthenopia
Conditions
Interventions
Injection for SC administration (120mg/syringe)
Tablet (50mg/tablet), oral
Locations
1
United States
NVision-EWEI-Torrance
Torrance, California, United States
Start Date
May 10, 2023
Primary Completion Date
November 9, 2023
Completion Date
November 9, 2023
Last Updated
June 3, 2024
NCT07463950
NCT07363824
NCT07396441
NCT05865457
NCT05865379
NCT07366944
Lead Sponsor
Nvision Laser Eye Centers
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions